Diphtheria is a disease caused by bacteria called Corynebacterium diphtheriae and Corynebacterium ulcerans. It can cause respiratory disorders that affect the other parts of the body, including the skin. People infected with diphtheria bacteria may develop symptoms or have no symptoms but may be carrying the bacteria and able to infect others.
The majority of people battling diphtheria will have a respiratory tract infection, with a sore throat and low grade fever in the first few days of the illness. Mild cases of the illness will not develop further symptoms. However, if the disease is more severe, a dense membrane will develop, which could be local for example, just on the tonsils or pharynx or could cover a wide area of the patient’s respiratory tract
Growing immunization programs and government support are likely to propel the market for diphtheria during the forecast period. A number of international and local health organizations including the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and Gavi, the Vaccine Alliance, are strongly promoting vaccination programs to eliminate diphtheria.
Governments across various countries are incorporating DTaP, Td, and Tdap vaccines into national immunization programs to ensure a wide coverage, especially among children aged five years and below. Additionally, foreign agency assistance and public-private partnerships are facilitating access to vaccines in the low and middle income countries (LMICs), where diphtheria outbreaks occur more often.
Public health programs, immunization in schools, and programs like routine immunization activities sponsored by UNICEF are also driving the market forward. As the activities increase in scope and magnitude, new demand for diphtheria vaccine, tests, and treatment will be seen in the market, ensuring proper prevention and control of disease.
The growing prevalence of diphtheria will be one of the key growth drivers to the market during the forecast period. Ongoing outbreaks in areas of historically low immunization coverage remind of the ongoing threat posed by this disease.
Although responding health authorities seek to quell outbreaks, there is renewed emphasis on raising immunization coverages and the immunization of susceptible groups. This increased awareness and concern are propelling diphtheria vaccine and concomitant therapeutic practices demand.
Moreover, the increasing reported case loads are encouraging governments and public health authorities to adopt aggressive vaccination campaigns and health education programs toward increased public awareness of the necessity of vaccination. Thus, the market can grow with additional investments in finding effective vaccines and treatments that can assist in controlling the resurgence of diphtheria and advancing public health on the international platform.
North America is expected to have highest market share in the diphtheria industry because of robust immunization practices, efficient healthcare systems, and adequate government support. The United States and Canada have all included diphtheria vaccines in routine immunization programs to achieve high coverage levels.
Additionally, organizations such as the Center for Disease Control and Prevention (CDC) and the Public Health Agency of Canada actively promote awareness of diphtheria vaccines and regular immunization campaigns. Leading pharma companies in the country and regular R&D activities also add up to the dominance.
Vaccines are expected to lead the diphtheria market by product type segment due to their pivotal role in prevention of disease and broad acceptance within immunization programs. Global health agencies, such as the World Health Organization (WHO), the Center for Disease Control and Prevention (CDC), and the Gavi, the Vaccine Alliance, highly recommend routine diphtheria vaccination as a component of the program of childhood immunization.
Governments of various countries have incorporated DTaP, Td, and Tdap vaccines into national immunization programs, and high levels of coverage, especially in infants and children under five, are assured. Furthermore, higher awareness of preventive healthcare, improved immunization coverage, and public and private institution support are among the major factors driving vaccine demand
The market players in diphtheria are employing various strategies to build their market positions and encourage innovation. One of the key ones is investing in research and development (R&D) so that the vaccines and the therapies available become better and meet increasing healthcare demands, as well as regulatory requirements.
Key players operating in the diphtheria market include:
NA
NA
NA
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Diphtheria Market
